Oppenheimer Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY)
Oppenheimer initiated coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) in a research note issued to investors on Monday, Marketbeat reports. The brokerage set an “outperform” rating and a $40.00 price target on the stock. Oppenheimer’s price objective points to a potential upside of 246.32% from the company’s previous close. Several other […]
Oppenheimer initiated coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) in a research note issued to investors on Monday, Marketbeat reports. The brokerage set an “outperform” rating and a $40.00 price target on the stock. Oppenheimer’s price objective points to a potential upside of 246.32% from the company’s previous close. Several other […]
